Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid long-term pick despite short-term risks.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face competition from cheaper generics.
What's Going On With Bristol Myers Squibb Stock On Monday?
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers.
Bristol Myers Squibb Tops Q4 Estimates
Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.
Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript
Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference over to Chuck Triano,
Bristol-Myers Squibb slips as 2025 outlook disappoints
Bristol-Myers Squibb (SMY) stock falls as its Q4 2024 results beat Street forecasts, but its 2025 outlook fell short of consensus. Read more here.
Bristol-Myers Squibb Stock Falls After Weak Guidance
Shares in Bristol-Myers Squibb traded lower after the drug maker gave 2025 guidance that undershot expectations. Bristol expects sales of about $45.5 billion in 2025, compared with the $46.3 billion estimate of analysts polled by FactSet.
Bristol-Myers Squibb Stock Slides On Weak 2025 Outlook, Retail Steps In To Buy The Dip
Bristol-Myers Squibb shares dropped nearly 4% Thursday morning, on track to hit their lowest point in over two weeks. Despite a strong fourth-quarter (Q4) performance, the company's 2025 outlook disappointed Wall Street,
Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent concerns. See why I rate BMY as a Hold.
Jim Cramer on Bristol Myers (BMY): “Knocking It Out of the Park” – Is the Comeback Legit?
Bristol-Myers Squibb Company (NYSE:BMY) had been left for dead on Wall Street, plagued by years of missed earnings and patent ...
FiercePharma6h
Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead
With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...
BioPharma Dive4d
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...
BioSpace6h
BMS Positions Breyanzi for Another Indication as LOE Woes Mount
Adding a new indication for the CAR T cell therapy could help BMS offset the loss-of-exclusivity headwinds it faces in the ...
Bristol Myers announces results from Phase 2 TRANSCEND FL trial
Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...
William Blair Has Bearish Forecast for BMY FY2026 Earnings
Equities research analysts at William Blair decreased their FY2026 earnings per share estimates for shares of Bristol-Myers ...
Bristol sees sharper 2025 revenue drop after better-than-forecast Q4
Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...
FierceBiotech3d
Bristol Myers backs out of Dupixent fight, axing allergy asset despite phase 3 win
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...